This is BrainsWay’s global website. The global website is not intended for persons in the United States and includes information on clinical indications that were not cleared by the FDA, which are subject to further US regulatory review for safety and efficacy. BrainsWay is cleared by the FDA only for patients with MDD who failed to respond to one or more anti-depressants in the current episode, and for patients with OCD as an adjunct treatment.
While patients are familiar with medication to treat depression, Deep TMS is providing a new option, particularly for treatment-resistant patients. WBBM describes how BrainsWay’s electromagnetic helmet is safer than medication and often cheaper when covered by insurance providers.